Sandostatin LAR

ApprovedSmall molecule

Novartis

Sandostatin LAR is one of 133 small molecule programs targeting Prader-Willi syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prader-Willi SyndromeActive, not recruiting

Pancreatic Neuroendocrine TumorActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

AcromegalyActive, not recruiting

Hypothalamic ObesityActive, not recruiting

Prader-Willi SyndromePhase 3

Active, not recruiting

Pancreatic Neuroendocrine TumorPhase 1

Active, not recruiting

Neuroendocrine CarcinomaPhase 2/Phase 3

Active, not recruiting

AcromegalyApproved

Active, not recruiting

Hypothalamic ObesityApproved

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Neuroendocrine Carcinoma

#DrugCompanyPhaseTrials

Tarlatamab-Dznl

Amgen

Phase 3

5 2

Sandostatin LAR

Novartis

Approved

1 3

Tuoyi

CCoherus Oncology, Inc.

Phase 3

1 4

Inlyta

PPrism Pharmaceuticals

Phase 3

1 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

—6

Wellcovorin

EEastern Cooperative Oncology Group

Keytruda

3 8

Camptosar

Pfizer

Phase 2

2 9

Opdivo

Bristol-Myers Squibb

Phase 2

2 10

Yervoy

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Pancreatic Neuroendocrine Tumor

NCT06505395

Clinical

Trials by Indication[1]

Acromegaly3 trials

Effects of Sandostatin LAR® in Acromegaly

Completed·—·Phase 4·NCT01424241·21 enrolled

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

Completed·UUniversity of Aarhus·Phase 4·NCT01618513·84 enrolled

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

Completed· Pfizer logo

Pfizer·Phase 4·NCT00068042·100 enrolled

Pancreatic Neuroendocrine Tumor2 trials

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06505395·90 enrolled

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Terminated·DDebiopharm International SA·Phase 1·NCT05364944·19 enrolled

Statin2 trials

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Suspended·AAzidus Brasil·Phase 1·NCT01086982·16 enrolled

Pegvisomant And Sandostatin LAR Combination Study

Completed· Pfizer logo

Pfizer·Phase 4·NCT00068029·75 enrolled

Neuroendocrine Carcinoma1 trial

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Unknown status·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2/3·NCT01744249·255 enrolled

Hypothalamic Obesity1 trial

Pediatric Hypothalamic Obesity

Completed· Novartis logo

Novartis·Phase 4·NCT00076362·60 enrolled

2 more indications

Prader-Willi syndrome1 trial

Prader-Willi Syndrome and Appetite

Terminated·UUniversity of British Columbia·Phase 3·NCT00175305·10 enrolled

Efficacy and Safety1 trial

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

Completed· Novartis logo

Novartis·Phase 4·NCT01278342·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Sandostatin LAR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sandostatin LAR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sandostatin LAR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Sandostatin LAR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Acromegaly3 trials

Pancreatic Neuroendocrine Tumor2 trials

Statin2 trials

Neuroendocrine Carcinoma1 trial

Hypothalamic Obesity1 trial

Prader-Willi syndrome1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News